|Day Low/High||233.70 / 245.98|
|52 Wk Low/High||64.88 / 290.23|
As we move through Georgia and see an end in sight to Covid, we need a gut check on what stocks are really going to go the distance.
The CRM software giant sports relatively low sales and billings multiples, and it stands to benefit in several ways from COVID's impact on enterprise tech adoption.
DocuSign, Lululemon Athletica, Splunk and Walmart are the diverse quartet of stocks that we're tracking.
These investors seem to buy with a gusto never before seen in my lifetime.
The quarter's results are fantastic, and the 'accelerating growth' is quite impressive to say the least.
At some point, there will be a fiscal support package passed -- but only when both sides think they can take the credit.
Also, Salesforce posts successful quarter and announces Slack acquisition to effectively take on Microsoft.
As long as the pandemic rages on, the stay-at-home thesis should stay strong.
Herds tend to be caught 'wrong footed' at turning points.
Plus, House Speaker Nancy Pelosi and Treasury Secretary Stephen Mnuchin agree to talk stimulus turkey.
The visible stories are almost all positive. The negative stories are almost all hidden at least when it comes to the stock market.
The course of least resistance for DOCU looks to be lower.
It looks like the Nasdaq 100 names have finished much of their correction and now it's the small-cap names' turn to take a hit.
As Covid-19 numbers rise in many states, it's time to get out of the restaurant stocks and look to Campbell Soup.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
Apple paves the way as pessimists were expecting a reversal that isn't happening.
DOCU is soaring in advance of reporting earnings this week, but here's what investors should consider.
DOCU continues to invest in identity and notary services, to remove the in-person elements from more and more transactions.
While still reporting healthy revenue and billings growth, Slack and some other software high-flyers are also seeing some demand headwinds.
I'm willing to expose myself to a limited level of downside equity risk and get paid to do it.
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
And the reality is that the more money you make, the more likely you can contribute to the causes that you care about.
SMAR is one of the few names not releasing earnings right now, and appears an attractive play.